Moderna's Massive Repricing
Moderna's MRNA shares surged nearly 177% in a single session after Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer treatment.
The INTerpath-001 trial met its primary endpoint for recurrence-free survival and a key secondary endpoint related to distant cancer spread in high-risk melanoma patients. The result is significant for personalized mRNA cancer therapy, although the treatment remains investigational and still requires regulatory approval.
Moderna's MRNA shares surged nearly 177% in a single session after Moderna and Merck announced positive Phase 3 results for their personalized mRNA cancer treatment.
The INTerpath-001 trial met its primary endpoint for recurrence-free survival and a key secondary endpoint related to distant cancer spread in high-risk melanoma patients. The result is significant for personalized mRNA cancer therapy, although the treatment remains investigational and still requires regulatory approval.